Selected article for: "combination therapy and immune therapy"

Author: Ylösmäki, Erkko; Fusciello, Manlio; Uoti, Arttu; Feola, Sara; Martins, Beatriz; Aalto, Karri; Hamdan, Firas; Ciaro, Jacopo; Viitala, Tapani; Cerullo, Vincenzo
Title: A personalized anti-cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella
  • Cord-id: cqb6115s
  • Document date: 2021_6_8
  • ID: cqb6115s
    Snippet: Common vaccines for infectious diseases have been repurposed as cancer immunotherapies. Intratumoural administration of these repurposed vaccines can induce immune cell infiltration into the treated tumour. Here, we have used an approved trivalent live attenuated measles, mumps, and rubella (MMR) vaccine in our previously developed PeptiENV anti-cancer vaccine platform. Intratumoural administration of this novel MMR-containing PeptiENV anti-cancer vaccine significantly increased both intratumour
    Document: Common vaccines for infectious diseases have been repurposed as cancer immunotherapies. Intratumoural administration of these repurposed vaccines can induce immune cell infiltration into the treated tumour. Here, we have used an approved trivalent live attenuated measles, mumps, and rubella (MMR) vaccine in our previously developed PeptiENV anti-cancer vaccine platform. Intratumoural administration of this novel MMR-containing PeptiENV anti-cancer vaccine significantly increased both intratumoural as well as systemic tumour-specific T cell responses. In addition, PeptiENV therapy, in combination with immune checkpoint inhibitor therapy, significantly improved tumour growth control and survival as well as increased the number of mice responsive to immune checkpoint inhibitor therapy.

    Search related documents: